Intuitive Surgical (NASDAQ:ISRG) Trading 0.1% Higher – Here’s Why

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) traded up 0.1% during trading on Tuesday . The stock traded as high as $599.00 and last traded at $596.42. 355,600 shares changed hands during trading, a decline of 79% from the average session volume of 1,707,671 shares. The stock had previously closed at $595.55.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Wells Fargo & Company lifted their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. JPMorgan Chase & Co. lifted their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Bernstein Bank lifted their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Raymond James lifted their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Stock Performance

The business’s 50 day moving average is $560.61 and its 200-day moving average is $521.21. The firm has a market capitalization of $214.12 billion, a price-to-earnings ratio of 93.79, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39.

Insiders Place Their Bets

In other Intuitive Surgical news, CFO Jamie Samath sold 108 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at $4,746,819.42. This trade represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,967,734. This represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,348 shares of company stock worth $3,587,582 in the last ninety days. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently made changes to their positions in ISRG. Atala Financial Inc bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $25,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $26,000. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Finally, Hurley Capital LLC bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $28,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.